LivaNova Reports Strong Q4 & FY25 Results, Raises 2026 Guidance, and Secures Major VNS Therapy Reimbursement Boost
LIVN has more than doubled off its 52-week low of $32.48 on elevated volume (2.6× avg).
Summary
LivaNova reported strong Q4 and full-year 2025 results, provided optimistic 2026 guidance, and announced a significant increase in CMS reimbursement for its VNS Therapy for Drug-Resistant Epilepsy, alongside FDA approval for a new digital health platform.
Key Events · Earnings and Guidance · LIVN
-
Strong Q4 and Full-Year 2025 Financial Performance
LivaNova reported fourth-quarter revenue of $360.9 million, up 12.1% reported and 9.5% constant-currency/organic. Full-year 2025 revenue reached $1.39 billion, an increase of 10.7% reported and 9.7% constant-currency. Adjusted diluted EPS for Q4 was $0.86 and for the full year was $3.90, reflecting strong operational execution.
-
Positive 2026 Guidance Issued
The company expects full-year 2026 constant-currency revenue growth between 6.0% and 7.0%. Adjusted diluted earnings per share for 2026 is projected to be in the range of $4.15 to $4.25, indicating continued growth.
-
Significant VNS Therapy Reimbursement Increase
Effective January 1, 2026, LivaNova received increased provider reimbursement from U.S. CMS for VNS Therapy for Drug-Resistant Epilepsy procedures, with hospital outpatient payments rising approximately 48% for new patient implants and 47% for end-of-service procedures, significantly reducing a known barrier to procedure penetration.
-
FDA Approval for Cloud-Based Digital Health Platform
The company received U.S. FDA approval for its cloud-based digital health platform, establishing a foundation to deliver greater convenience and deeper insights throughout the DRE patient journey.
Analysis · LIVN · Industrial Applications And Services
LivaNova PLC delivered robust financial performance in Q4 and full-year 2025, marked by double-digit revenue growth and expanding operating margins. The company also issued positive guidance for 2026, projecting continued revenue growth and increased adjusted diluted earnings per share. A significant catalyst is the increased U.S. CMS reimbursement for VNS Therapy for Drug-Resistant Epilepsy procedures, which is expected to substantially reduce a key barrier to market penetration. Additionally, FDA approval for a new cloud-based digital health platform strengthens the foundation for future DRE patient management. While the company recorded a substantial one-time SNIA environmental liability expense impacting GAAP results, the focus on adjusted operational metrics and future growth drivers suggests a positive outlook.
At the time of this filing, LIVN was trading at $69.05 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.8B. The 52-week trading range was $32.48 to $69.52. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.